IP Library Granted Patent US 8,377,879
Granted Patent B2
US 8,377,879 · App. 13/187,956 · Granted Feb 19, 2013

Follicle stimulating hormone superagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,879
App. No.
13/187,956
Granted
Feb 19, 2013
Kind
B2
Abstract

This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.

Claims (10)

1. A method of inducing superovulation in a cow comprising:

administering an effective amount of a superactive follicle stimulating hormone (FSH) to said cow,

wherein said superactive FSH is bovine FSH with an alpha chain comprising basic amino acid substitutions at positions 17, 18, 20 and 24; and

wherein the alpha chain further comprises an ANTIV (SEQ ID NO: 3) N-terminal extension.

2. The method of claim 1 , wherein superovulation is characterized by an increase in oocyte number as compared to a like animal receiving the same amount of recombinant wild type bovine FSH.

3. The method of claim 2 , wherein the average oocyte number increases at least about 10% as a result of administration of said superactive bovine FSH at the maximally effective dose for oocyte number.

4. The method of claim 1 , wherein the basic amino acid is an arginine, a lysine, or a histidine.

5. The method of claim 1 , wherein the amino acid substitutions at positions 17, 18, 20 and 24 are arginine substitutions.

6. The method of claim 1 , wherein said ANTIV (SEQ ID NO: 3) extension prolongs the half life of the superactive FSH.

7. The method of claim 1 , wherein said superactive FSH is administered by injection or ingestion.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2013
From: PALADIN LABS INC.
To: TROPHOGEN, INC.
Reel/Frame 031004/0009 →
ASSIGNMENT OF ASSIGNEES' SECURITY INTEREST AT REEL 028069 AND FRAME 0928 Recorded Jul 10, 2013
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
To: PALADIN LABS INC.
Reel/Frame 030783/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2012
From: SZKUDLINSKI, MARIUSZ W.; WEINTRAUB, BRUCE D.
To: TROPHOGEN, INC.
Reel/Frame 028706/0713 →
SECURITY AGREEMENT Recorded Apr 18, 2012
From: BIONICHE LIFE SCIENCES INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
Reel/Frame 028069/0928 →